A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 ...
Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...
Myriad Genetics (MYGN) was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to ...
10d
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was ...
Recent advances in genetic testing technology have transformed personal health care from general guidelines to precise, ...
The chemotherapy drugs 5-FU and capecitabine could harm or kill you if you have a variant in the DPYD gene. Request genetic testing before you take these drugs.
Genetic testing could lower the risk of adverse drug reactions for thousands of patients with cancer
A new study led by Genomics England and Queen Mary University of London estimates that genetic testing could identify ...
In addition, the contract includes pharmacogenetic testing. Pharmacogenetics uses genomic information to determine how patients will respond to certain medications--an important component of ...
The goal of this article is to extend the use of our test adoption model to the analysis of several oncology related pharmacogenomic tests introduced over the last 12 years. Adoption modifiers ...
It comes at a time when advanced diagnostic tests to gauge "biological age" are becoming popular among the wealthy and health-conscious. Good balance, muscle strength, and an efficient gait or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback